Page 43 - 2019_07 resto del Mondo-web

In vivo manipulation of Treg cells
148. Guilliams M, Bosschaerts T, Herin M, et al. Experimental expansion of the regulatory T cell population increases resistance to African trypanosomiasis. J Infect Dis. 2008;198(5):781-791.
149. Azuma H, Isaka Y, Li X, et al. Superagonistic CD28 antibody induces donor-specific toler- ance in rat renal allografts. Am J Transplant. 2008;8(10):2004-2014.
150. Kitazawa Y, Fujino M, Sakai T, et al. Foxp3- expressing regulatory T cells expanded with CD28 superagonist antibody can prevent rat cardiac allograft rejection. J Heart Lung Transplant. 2008;27(4):362-371.
151. Kitazawa Y, Fujino M, Li XK, et al. Superagonist CD28 antibody preferentially expanded Foxp3-expressing nTreg cells and prevented graft-versus-host diseases. Cell Transplant. 2009;18(5):627-637.
152. Kitazawa Y, Li XK, Liu Z, et al. Prevention of graft-versus-host diseases by in vivo supCD28mAb-expanded antigen-specific nTreg cells. Cell Transplant. 2010;19(6):765- 774.
153. Beyersdorf N, Ding X, Hunig T, Kerkau T. Superagonistic CD28 stimulation of allogene- ic T cells protects from acute graft-versus- host disease. Blood. 2009;114(20):4575-4582.
154. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti- CD28 monoclonal antibody TGN1412. The New England journal of medicine. 2006;355(10):1018-1028.
155. Peine M, Marek RM, Lohning M. IL-33 in T Cell Differentiation, Function, and Immune Homeostasis. Trends Immunol. 2016;37(5): 321-333.
156. Griesenauer B, Paczesny S. The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases. Front Immunol. 2017;8:475.
157. Paczesny S, Hakim FT, Pidala J, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. Biol Blood Marrow Transplant. 2015;21(5):780-792.
158. Matta BM, Lott JM, Mathews LR, et al. IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2+ regulatory T cells. J Immunol. 2014;193(8):4010-4020.
159. Matta BM, Turnquist HR. Expansion of Regulatory T Cells In Vitro and In Vivo by IL- 33. Methods Mol Biol. 2016;1371:29-41.
160.Siede J, Frohlich A, Datsi A, et al. IL-33 Receptor-Expressing Regulatory T Cells Are Highly Activated, Th2 Biased and Suppress CD4 T Cell Proliferation through IL-10 and TGFbeta Release. PLoS One. 2016;11(8): e0161507.
161. Schiering C, Krausgruber T, Chomka A, et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature. 2014;513(7519):564-568.
162. Xu L, Li W, Wang X, et al. The IL-33-ST2- MyD88 axis promotes regulatory T cell pro- liferation in the murine liver. Eur J Immunol. 2018;48(8):1302-1307.
163. Turnquist HR, Zhao Z, Rosborough BR, et al. IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell- dependent promotion of cardiac allograft survival. J Immunol. 2011;187(9): 4598-4610.
164.Brunner SM, Schiechl G, Falk W, et al. Interleukin-33 prolongs allograft survival during chronic cardiac rejection. Transpl Int. 2011;24(10):1027-1039.
165. Biton J, Khaleghparast Athari S, Thiolat A, et al. In Vivo Expansion of Activated Foxp3+
Regulatory T Cells and Establishment of a Type 2 Immune Response upon IL-33 Treatment Protect against Experimental Arthritis. J Immunol. 2016;197(5):1708-1719.
166. Popovic B, Golemac M, Podlech J, et al. IL- 33/ST2 pathway drives regulatory T cell dependent suppression of liver damage upon cytomegalovirus infection. PLoS Pathog. 2017;13(4):e1006345.
167. Reichenbach DK, Schwarze V, Matta BM, et al. The IL-33/ST2 axis augments effector T- cell responses during acute GVHD. Blood. 2015;125(20):3183-3192.
168. Matta BM, Reichenbach DK, Zhang X, et al. Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD. Blood. 2016;128(3): 427-439.
169. Gatza E, Rogers CE, Clouthier SG, et al. Extracorporeal photopheresis reverses exper- imental graft-versus-host disease through regulatory T cells. Blood. 2008;112(4):1515- 1521.
170. Broxmeyer HE, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 2005;201(8):1307-1318.
171. Kean LS, Sen S, Onabajo O, et al. Significant mobilization of both conventional and regu- latory T cells with AMD3100. Blood. 2011;118(25):6580-6590.
172.Ukena SN, Velaga S, Goudeva L, et al. Human regulatory T cells of G-CSF mobi- lized allogeneic stem cell donors qualify for clinical application. PLoS One. 2012;7(12): e51644.
173. Robinson TM, O'Donnell PV, Fuchs EJ, Luznik L. Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Semin Hematol. 2016;53(2):90-97.
174. Ganguly S, Ross DB, Panoskaltsis-Mortari A, et al. Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice. Blood. 2014;124 (13):2131-2141.
175.Cooper ML, Choi J, Karpova D, et al. Azacitidine Mitigates Graft-versus-Host Disease via Differential Effects on the Proliferation of T Effectors and Natural Regulatory T Cells In Vivo. J Immunol. 2017;198(9):3746-3754.
176.Ashami K, DiPersio JF, Choi J. Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD. Oncotarget. 2018;9(87): 35721-35722.
177.Choi J, Cooper ML, Staser K, et al. Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-ver- sus-host disease. Leukemia. 2018;32(11): 2483-2494.
Rojas G. Combining computational and experimental biology to develop therapeuti- cally valuable IL2 muteins. Semin Oncol. 2018;45(1-2):95-104.
182. Pillai AB, George TI, Dutt S, Strober S. Host natural killer T cells induce an interleukin-4- dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. Blood. 2009;113(18):4458-4467.
183. Schneidawind D, Pierini A, Alvarez M, et al. CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells. Blood. 2014;124(22):3320- 3328.
184.Du J, Paz K, Thangavelu G, et al. Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regula- tory T cells. Blood. 2017;129(23):3121-3125.
185.Kuns RD, Morris ES, Macdonald KP, et al. Invariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after alpha-galactosylceramide administra- tion. Blood. 2009;113(23):5999-6010.
186. Harvill ET, Fleming JM, Morrison SL. In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation. J Immunol. 1996;157(7):3165-3170.
187. Carmenate T, Ortiz Y, Enamorado M, et al. Blocking IL-2 Signal In Vivo with an IL-2 Antagonist Reduces Tumor Growth through the Control of Regulatory T Cells. J Immunol. 2018;200(10):3475-3484.
188.Mitra S, Ring AM, Amarnath S, et al. Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. Immunity. 2015;42(5):826-838.
189.Trotta E, Bessette PH, Silveria SL, et al. A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mech- anism. Nat Med. 2018;24(7):1005-1014.
190.Slavin S, Fuks Z, Kaplan HS, Strober S. Transplantation of allogeneic bone marrow without graft-versus-host disease using total lymphoid irradiation. J Exp Med. 1978;147 (4):963-972.
191.Pillai V, Maude SL. CART attack. Blood. 2017;130(2):229.
192. Periasamy S, Dhiman R, Barnes PF, et al. Programmed death 1 and cytokine inducible SH2-containing protein dependent expan- sion of regulatory T cells upon stimulation With Mycobacterium tuberculosis. J Infect Dis. 2011;203(9):1256-1263.
193.Zhou Q, Munger ME, Highfill SL, et al. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lympho- cytes in advanced acute myeloid leukemia. Blood. 2010;116(14):2484-2493.
178.
Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, et al. Selective oral ROCK2 inhibitor down- regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. 2014;111(47): 16814-16819.
194.
195.
Franceschini D, Paroli M, Francavilla V, et al. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chroni- cally infected with HCV. J Clin Invest. 2009;119(3):551-564.
Karim R, Jordanova ES, Piersma SJ, et al. Tumor-expressed B7-H1 and B7-DC in rela- tion to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res. 2009;15(20):6341-6347.
179. Zanin-Zhorov A, Flynn R, Waksal SD, Blazar BR. Isoform-specific targeting of ROCK pro- teins in immune cells. Small GTPases. 2016;7(3):173-177.
180.Spangler JB, Trotta E, Tomala J, et al. Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy. J Immunol. 2018;201(7):2094-2106.
181. Leon K, Garcia-Martinez K, Carmenate T,
196. Asano T, Meguri Y, Yoshioka T, et al. PD-1 modulates regulatory T-cell homeostasis dur- ing low-dose interleukin-2 therapy. Blood. 2017;129(15):2186-2197.
197.
Singh AK, Porrata LF, Aljitawi O, et al. Fatal GvHD induced by PD-1 inhibitor pem- brolizumab in a patient with Hodgkin's lym- phoma. Bone Marrow Transplant. 2016;51 (9):1268-1270.
haematologica | 2019; 104(7)
1321